Every 8-K that AYTU BioPharma, Inc. (AYTU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AYTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AYTU filings page.
Aytu BioPharma, Inc. (AYTU) reported fiscal 2026 Q4 and full-year results highlighting early EXXUA traction and mixed legacy portfolio trends. Q4 2026 net revenue was $16.1 million, up 6.4% from $15.1 million, with EXXUA contributing $3.9 million and the ADHD Portfolio $10.4 million.
Q4 net loss was approximately break-even at less than $0.1 million, versus a $19.8 million loss a year earlier, and Adjusted EBITDA was $0.5 million. For fiscal 2026, net revenue was $57.6 million versus $66.4 million, and net loss was $14.3 million versus $13.6 million. Full-year Adjusted EBITDA declined to -$3.7 million from $9.2 million as the company increased EXXUA commercialization investments.
EXXUA generated $6.6 million in fiscal 2026 net revenue, including 3,323 prescriptions in Q4, up about 138% from 1,398 in Q3. As of June 30, 2026, cash and equivalents were $26.3 million and stockholders’ equity was $35.3 million, aided by reclassification that reduced derivative warrant liabilities to $1.2 million.
Aytu BioPharma, Inc. has mutually agreed with Lannett Company, Inc. to terminate their exclusive license agreement for Metadate CD, effective June 23, 2026. This ends Aytu’s licensed rights under the Metadate Agreement, except for certain surviving provisions described in a separate Termination Agreement.
Aytu may continue to sell and distribute its remaining Metadate CD inventory at its own discretion and must keep providing royalty reports and paying related royalties until those inventory sales stop. Net revenue from Metadate CD reported for the quarter ended March 31, 2026 was $49,000, indicating the product’s relatively modest contribution before termination.
Aytu BioPharma reported a challenging fiscal 2026 third quarter as it ramps up the launch of EXXUA for major depressive disorder. Net revenue was $12.4 million versus $18.5 million a year earlier, reflecting lower sales in ADHD and pediatric products as resources shifted toward EXXUA and generic competition emerged.
EXXUA generated $2.4 million in its early launch quarter, while ADHD portfolio revenue was $9.1 million and pediatric revenue was $0.9 million. The company posted a net loss of $5.6 million, or $0.53 per basic share, compared with net income of $4.0 million in the prior-year quarter, influenced by a $1.3 million derivative warrant liability loss versus a prior gain.
Adjusted EBITDA was $(2.8) million, down from $3.9 million, as Aytu invested in the EXXUA launch. Cash and cash equivalents were $26.7 million at March 31, 2026. By amending and restating certain warrants, the company reduced derivative warrant liabilities by $26.4 million and increased stockholders’ equity to $35.1 million.
Aytu BioPharma, Inc. entered into amended and restated warrant agreements with institutional investors on March 31, 2026, replacing June 2023 and June 2025 prefunded and Tranche A warrants with revised beneficial ownership blockers. The new language clarifies that stockholders cannot vote to amend or change these blockers.
Previously, ambiguity around the blockers led the company, under ASC Topic 480 and ASC Topic 815, to classify the warrants as liabilities, recording a warrant liability of $18.1 million for the quarter ended September 30, 2025 and $25.2 million for the quarter ended December 31, 2025. Following the amendments, the company expects its warrant liability to decrease and its equity value to increase by the same amount.
Aytu BioPharma, Inc. announced that it issued a press release detailing its fiscal 2026 second quarter operational and financial results. The company also scheduled a public conference call and live audio webcast on February 3, 2026 at 4:30 p.m. Eastern time to discuss these results and answer questions.
The call is accessible by webcast and telephone, with replay options available on Aytu’s website and via telephone, subject to the company’s discretion. The press release containing the results is furnished as an exhibit, but is not treated as filed for liability purposes under federal securities laws.
Aytu BioPharma, Inc. filed a current report describing investor communications held on January 20, 2026. The company issued a press release titled “Aytu BioPharma Recaps Investor Day Held on January 20, 2026,” which is furnished as an exhibit. Aytu also posted an investor presentation on its website used in an investor meeting that same day.
The presentation, attached as another exhibit, includes information about the EXXUA™ (gepirone) extended-release tablets opportunity, giving investors additional detail on this product. Both the press release and the presentation are furnished, not filed, meaning they are not automatically incorporated into other securities law filings unless specifically referenced.
AYTU BioPharma furnished an update on its fiscal 2026 first quarter operational and financial results via a press release and scheduled a conference call and live audio webcast for November 13, 2025 at 4:30 p.m. Eastern time to discuss the results and take questions.
The webcast and telephone access details are provided in the press release, with a replay available on the company’s website and by phone at the company’s discretion. The press release is furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act unless specifically incorporated by reference.
Aytu BioPharma filed a Form 8-K reporting that on September 23, 2025 it issued a press release announcing its fiscal 2025 full year and fourth quarter operational and financial results and scheduled a conference call and live audio webcast for September 23, 2025 at 4:30 p.m. Eastern to discuss those results. The filing notes the press release is furnished as Exhibit 99.1 and explains that the exhibit is furnished, not filed, for Exchange Act purposes. The company states the call will be publicly accessible via webcast and telephone, with a replay available at the company’s discretion on its website and by telephone replay. No financial metrics, guidance, or other substantive disclosures are included in the 8-K text itself.
On June 20, 2025, Aytu BioPharma, Inc. (AYTU) executed Amendment No. 6 to its Loan and Security Agreement with Eclipse Business Capital. The amendment affects both the company’s term loan and revolving credit facility.
- Maturity extension: The $13.0 million Eclipse Term Loan and the Eclipse Revolving Loan now mature on June 12, 2029, giving AYTU an additional four-year runway.
- Incremental liquidity: A $1.5 million incremental advance was added to the revolving facility, priced at SOFR + 5.50%.
- Amortisation schedule: Repayment of the incremental advance begins August 1, 2025 at $125,000 per month until the advance is fully repaid.
- Borrowing-base flexibility: The amendment increases borrowing-base availability by permitting 25% concentration limits on certain independent pharmacy distributors.
- Regulatory disclosure: The transaction constitutes a direct financial obligation (Item 2.03). A press release dated June 23, 2025 (Exhibit 99.1) publicised the amendment; no earnings or operational updates were included.
The deal strengthens near-term liquidity and extends debt maturities, though at a relatively high floating rate and with scheduled principal reductions that will affect future cash flow.